Acura investors euphoric over US FDA OK of oxycodone painkiller
This article was originally published in Scrip
Executive Summary
Shares of Acura Pharmaceuticals skyrocketed as high as 75.7%, or $2.93, on 20 June on word that the US FDA approved Oxecta (oxycodone HCI) as a therapy to manage acute and chronic moderate-to-severe pain where the use of an opioid analgesic is appropriate.